Skip to main content
SearchLogin or Signup

Review 1: "Genetic association analysis of SARS-CoV-2 infection in 455,838 UK Biobank participants"

The authors looked for the genetic loci of COVID-19 risk and severity in the UK biobank. Further studies are needed to pinpoint bona fide loci associated with COVID19 severity and susceptibility, though this study method is deemed reliable by reviewers.

Published onDec 09, 2020
Review 1: "Genetic association analysis of SARS-CoV-2 infection in 455,838 UK Biobank participants"
1 of 2
key-enterThis Pub is a Review of
Genetic association analysis of SARS-CoV-2 infection in 455,838 UK Biobank participants

ABSTRACT Background Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes Coronavirus disease-19 (COVID-19), a respiratory illness with influenza-like symptoms that can result in hospitalization or death. We investigated human genetic determinants of COVID-19 risk and severity in 455,838 UK Biobank participants, including 2,003 with COVID-19.Methods We defined eight COVID-19 phenotypes (including risks of infection, hospitalization and severe disease) and tested these for association with imputed and exome sequencing variants.Results We replicated prior COVID-19 genetic associations with common variants in the 3p21.31 (in LZTFL1) and 9q34.2 (in ABO) loci. The 3p21.31 locus (rs11385942) was associated with disease severity amongst COVID-19 cases (OR=2.2, P=3×10−5), but not risk of SARS-CoV-2 infection without hospitalization (OR=0.89, P=0.25). We identified two loci associated with risk of infection at P<5×10−8, including a missense variant that tags the ε4 haplotype in APOE (rs429358; OR=1.29, P=9×10−9). The association with rs429358 was attenuated after adjusting for cardiovascular disease and Alzheimer’s disease status (OR=1.15, P=0.005). Analyses of rare coding variants identified no significant associations overall, either exome-wide or with (i) 14 genes related to interferon signaling and reported to contain rare deleterious variants in severe COVID-19 patients; (ii) 36 genes located in the 3p21.31 and 9q34.2 GWAS risk loci; and (iii) 31 additional genes of immunologic relevance and/or therapeutic potential.Conclusions Our analyses corroborate the association with the 3p21.31 locus and highlight that there are no rare protein-coding variant associations with effect sizes detectable at current sample sizes. Our full analysis results are publicly available, providing a substrate for meta-analysis with results from other sequenced COVID-19 cases as they become available. Association results are available at

RR:C19 Evidence Scale rating by reviewer:

  • Reliable. The main study claims are generally justified by its methods and data. The results and conclusions are likely to be similar to the hypothetical ideal study. There are some minor caveats or limitations, but they would/do not change the major claims of the study. The study provides sufficient strength of evidence on its own that its main claims should be considered actionable, with some room for future revision.



The authors use genetic data from UK Biobank participants to determine whether certain loci are associated with COVID-19 susceptibility or severity upon contraction of the disease. In the course of their study, they attempt to reproduce the findings of prior studies as well as look for associations between their phenotypes and potentially informative or novel sites. The analyses performed appear rigorous to me, though I have some concerns about potential biases in the sample of infected individuals as well as insufficient sample sizes. That said, these challenges are functionally impossible to fully confront in the context of the ongoing pandemic, and the authors do discuss them in the text and account for other phenotypes in certain situations (e.g., Alzheimer’s).

Overall, I think the analyses presented are informative, providing helpful support and context to previous studies which are also likely to suffer from potential difficulties in sample collection. In particular, confirmation (or the lack thereof) of loci which may be associated with population structure is critical to avoid spending resources improperly and to better understand how to treat diverse populations. This study makes headway in these directions, including, for instance, the analysis of the ABO locus. I found the authors’ interpretation of their findings to be grounded and aware of potential limitations. Though few loci were identified, I feel the attempts at replication and investigation of loci with clinical significance is important to the community as additional studies are released. The exposition is lucid and the results dashboard a helpful addition to improve accessibility to the reader.

In light of the rapid developments in this area of research, I think the manuscript can be accepted in its current state, though I would be interested to see follow ups with additional infected patients or loci identified by other groups for a more formal review process.


No comments here